Dupilumab is efficacious in patients with prurigo nodularis regardless of history of atopic comorbidities: pooled results from two phase 3 trials (LIBERTY-PN PRIME and PRIME2)
BRITISH JOURNAL OF DERMATOLOGY（2024）
关键词
dupilumab,prurigo nodularis,atopy,itch,skin -lesions
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要